Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer

Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression

The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an objective progression of the disease.

Same as brief summary

Inclusion Criteria:

• Male 18 years and older
• Histologically confirmed prostate adenocarcinoma Stage pathological tumor-2 (pT2)
• Post radical Primary Prostatectomy
• Completion of DCVAC/PCa arm in Study SP003, without objective progression of the disease

Exclusion Criteria:

• Prior androgen deprivation therapy for prostate cancer
• Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater
• Other uncontrolled intercurrent illness
• Treatment with immunotherapy against PCa
• Clinically significant cardiovascular disease
• Active autoimmune disease requiring treatment